People
Charles M. Lieber is currently on paid leave from Harvard’s chemistry department after his arrest in January on charges of lying to the U.S. government about funds received from China.
A 41-year-old man from Richland, Wash. was convicted on 47 counts of fraud and drug related charges on Oct. 1, according to the U.S. Justice Department’s Eastern District of Washington.
In the study published October 7th in Science Translational Medicine, Dr. Weiss et al shared that immunocytokines delivered systemically were effective in mice models and a pilot human trial.
10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
There is little doubt that CRISPR gene editing is and will continue to revolutionize biology and medicine. The Nobel Committee confirmed their belief in that by awarding the Nobel Prize in Chemistry to Emmanuelle Charpentier and Jennifer A. Doudna for their discovery and development of CRISPR.
Michael Haas, Medasource’s Pharmaceutical & Life Sciences Vertical Director, describes the company as a “national healthcare consulting and project services company.”
In his resignation, Bright said that the Trump administration “ignores scientific expertise, overrules public health guidance and disrespects career scientists.”
Visible Genomics, a Chicago-area genetics testing company and founders of a non-invasive genetic eye test that determines a patient’s likelihood of contracting Age-Related Macular Degeneration (AMD), announced today that it has appointed Dr. Barry Eiden, Dr. Steven Ferrucci, Dr. Alan Glazier, and Dr. Treacy Adamo to its board of clinical advisors.
The probability of dying from COVID-19 depends more on age than gender, race or ethnicity, according to the first U.S. statewide random sample study of SARS-CoV-2 prevalence and fatalities.
PRESS RELEASES